- Conditions
- Papillomavirus Infections
- Interventions
- 851B
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 535
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Oropharyngeal Carcinoma, Human Papilloma Virus
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Cancer Prevention
- Interventions
- Salud en Mis Manos - Dissemination and Implementation Assistance, Salud en Mis Manos- Usual Implementation Practice
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 74 Years · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
- Interventions
- Cantharidin
- Combination Product
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Saint Augustine, Florida • Plainfield, Indiana • Boardman, Ohio + 1 more
- Conditions
- HIV Infections
- Interventions
- Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 27 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
- Conditions
- Warts, Warts Hand, Verruca
- Interventions
- CellFX Device
- Device
- Lead sponsor
- Pulse Biosciences, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Diego, California • Rochester, New York + 2 more
- Conditions
- Human Papillomavirus Infection
- Interventions
- Communication Intervention, Communication Skills Training, Healthcare Activity, Survey Administration
- Other · Behavioral
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Papilloma Viral Infection
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 9 Years to 17 Years · Female only
- Enrollment
- 1,321 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Tucker, Georgia • Baltimore, Maryland • Kansas City, Missouri + 4 more
- Conditions
- Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
- Interventions
- TST005
- Drug
- Lead sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Dallas, Texas • San Antonio, Texas
- Conditions
- HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
- Interventions
- ABI-1968
- Drug
- Lead sponsor
- Antiva Biosciences
- Industry
- Eligibility
- 27 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more
- Conditions
- Cervical Cancer, Precancerous Condition
- Interventions
- survey administration
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 24 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 8
- States / cities
- Cleveland, Ohio
- Conditions
- CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
- Interventions
- Artesunate vaginal insert, Placebo vaginal insert
- Drug
- Lead sponsor
- Frantz Viral Therapeutics, LLC
- Industry
- Eligibility
- 25 Years to 100 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Interventions
- Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab
- Biological · Procedure · Other + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Papillomavirus Infections
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years to 65 Years · Female only
- Enrollment
- 303 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Human Papilloma Virus, Cervical Dysplasia
- Interventions
- Educational video
- Other
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Meningococcal Meningitis
- Interventions
- Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 801 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Fremont, California • Madera, California + 14 more
- Conditions
- Human Papillomavirus (HPV)-Related Malignancies, Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
- Interventions
- Ribavirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Interventions
- Utomilumab, ISA101b
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HPV Infection, Preventive Health Services
- Interventions
- Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard)
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Wichita, Kansas
- Conditions
- Papillomavirus Infections
- Interventions
- 9vHPV Vaccine, Placebo (Saline for Injection)
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 20 Years to 45 Years · Male only
- Enrollment
- 6,033 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Northridge, California • Rialto, California • Simi Valley, California + 28 more
- Conditions
- Epidemiology
- Interventions
- Focus Group, Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
- Interventions
- PDS0101, M7824, NHS-IL12
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Interventions
- VP-102, Vehicle
- Combination Product
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Saint Augustine, Florida • Plainfield, Indiana • Hunt Valley, Maryland + 3 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 231
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 179 more